The mechanism of the transmetalation step in the metal-carbon bond-formation process catalyzed by palladium complexes has been studied by spectroscopic and kinetic methods. The reaction of properly designed model complexes [structure: see text], resulting from oxidative addition of a Mo-I moiety to a palladium center, with aryltributyltinacetylides Bu(3)Sn-C [triple bond] C-(p-XC(6)H(4)) (11a, X = H; 11b, X = Cl) yields the products of transmetalation [structure: see text] (5a,b). The reaction, which shows a strong dependence on the nature of the phosphine ligand PR(3) (Ph > Bu > Me) and less so on the nature of the p-substituent X group, proceeds through two competing pathways, depending on the initial concentration of substrate. At high [3] (approximately equal to 10(-2) M), the transmetalation proceeds through an intermediate species (12) formed by the interaction of complex 3 with 11a. This associative complex accumulates in the presence of added PPh(3) and has been characterized spectroscopically. At low [3] (approximately equal to 10(-4) M), the reaction rate shows an inverse dependence on the concentration of the complex. This is due to the formation of a solvent-coordinate species (13), in which PPh(3) has been substituted by a dimethylformamide (DMF) molecule, as shown by UV-vis and (31)P NMR spectroscopy. Values of k(obs) depend on the concentration and nature of the aryltributyltinacetylides, in agreement with the existence of a kinetically detectable intermediate. A dimeric iodide bridged complex [structure: see text](14) has been obtained during attempts at isolating 13, which changes quantitatively into 13 upon dissolution in DMF and reacts with 11a to give the transmetalation product.
No takes yet. Share an insight, caveat, or question.
Ricci et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: